מן הרשת 27.08.202017:44 Selpercatinib Aimed at RET-Altered Cancers A remarkable increase has occurred in the number of highly targeted drugs that have efficacy in patients with advanced cancers that harbor specific genomic alterations NEJM
מן הרשת 27.08.202017:42 Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer RET fusions are oncogenic drivers in 1 to 2% of non–small-cell lung cancers (NSCLCs). In patients with RET fusion–positive NSCLC, the efficacy and safety of selective RET inhibition are unknown NEJM
מן הרשת 17.08.202017:32 The Effect of Advances in Lung-Cancer Treatment on Population Mortality Although overall mortality from lung cancer has been declining in the United States, little is known about mortality trends according to cancer subtype at the population level because death certificates do not record subtype information NEJM
מן הרשת 10.08.202013:00 eXalt3 Findings Support Ensartinib as a First-Line Treatment Option in ALK-positive NSCLC By Kara Nyberg, PhD IASLC
מן הרשת 09.08.202016:26 Dual Immunotherapy Prolongs Survival While Avoiding Chemotherapy in Malignant Pleural Mesothelioma By Kara Nyberg, PhD Iaslc
מן הרשת 03.08.202015:45 New androgen receptor structure suggests prostate cancer treatment options The androgen receptor is the primary driver of the initiation and growth of prostate cancer, the second-leading cause of death in men ecancer
מן הרשת 30.07.202012:12 EAU 2020: Young Men Should Not Be Excluded From Active Surveillance for Prostate Cancer on the Basis of Age Alone This outcome of a comparison of radiological and clinical progression in men who began active surveillance at age ≤65 vs those >65 years was reported as part of the virtual 35th Annual Congress of the European Association of Urology Urology
מן הרשת 30.07.202012:09 EAU 2020: Pembrolizumab + Nab-Paclitaxel Shows Promise as Second- to Third-Line Therapy for Advanced Urothelial Carcinoma Urology
מן הרשת 30.07.202012:06 EAU 2020: Enzalutamide Demonstrates Positive Results in Metastatic, Castration-Resistant Prostate Cancer Urology
מן הרשת 27.07.202014:43 EAU 2020: Recurrence after Radical Prostatectomy Summary from the EAU Prostate Cancer Guidelines Panel Uro Today
מן הרשת 27.07.202014:42 EAU 2020: The Best Sequence for M+ Castrate-resistant Prostate Cancer in 2020 Dr. Alison Birtle gave a talk on the ever-changing treatment paradigm of advanced prostate cancer Uro Today
מן הרשת 27.07.202014:38 EAU 2020: Case-based Debate PSMA-targeted Radioligand Therapy Which Patients, Which Stages? Treatment Options: Medical oncologist, Nuclear medicine, and Urologist Perspectives Uro Today
מן הרשת 27.07.202014:36 Impact of Sequencing of Androgen Suppression and Radiotherapy on Testosterone Recovery in Localized Prostate Cancer International Journal of Radiation Oncology
מן הרשת 27.07.202014:34 Risk of Metastasis in Men With Grade Group 2 Prostate Cancer Managed With Active Surveillance The Journal of Urology
מן הרשת 27.07.202014:33 Oral GnRH Receptor Antagonist Relugolix as Neoadjuvant/Adjuvant ADT to EBRT in Localized Intermediate-Risk Prostate Cancer European Association of Urology
תגובות אחרונות